<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEPHENYTOIN</span><br/>(me-fen'i-toyn)<br/><span class="topboxtradename">Mesantoin<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span>; <span class="classification">hydantoin</span><br/><b>Prototype: </b>Phenytoin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Precise mechanism of anticonvulsant action unknown, but drug use is accompanied by reduced voltage, frequency and spread of
         electrical discharges within the motor cortex, resulting in seizure activity inhibition. Reported to have more sedative and
         hypnotic action than phenytoin. Causes serious toxic reactions more frequently than phenytoin, including fatal blood dyscrasias.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Controls seizure activity of the cortex of the brain. Relatively ineffective for petit mal seizures.</p>
<h1><a name="uses">Uses</a></h1>
<p>Control of grand mal, focal, Jacksonian, and psychomotor seizures in patients refractory to less toxic anticonvulsants. Usually
         used concomitantly with other antiepilepsy agents.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Use in conjunction with oxazolidinedione anticonvulsant agents [e.g., paramethadione, trimethadione (toxic synergism)] lactation.
         Safety during pregnancy (category D) is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of drug hypersensitivities.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg/d during first week, increase weekly to 200600 mg/d in 3 divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 315 mg/kg/d in 3 divided doses, increase weekly to 100400 mg/d in 3 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Given with food to reduce GI distress.</li>
<li>Do not increase dose until it is taken for at least 1 wk.</li>
<li>Change from another anticonvulsant agent gradually by increasing dose at weekly intervals and reducing dose of drug to be
            discontinued over 36 wk.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, dizziness. <span class="typehead">Skin:</span> Skin and mucous membrane manifestations (<span class="speceff-life">exfoliative dermatitis</span>, erythema multiforme, toxic epidermal necrolysis, other skin rashes). <span class="typehead">Hematologic:</span> <span class="speceff-life">Blood dyscrasias (leukopenia, eutropenia, agranulocytosis, thrombocytopenia, aplastic anemia</span>). <span class="typehead">GI:</span> Hepatic damage. <span class="typehead">Body as a Whole:</span> Periarteritis nodosa, systemic lupus erythematosus syndrome. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Phenytoin (hydantoins) may produce lower than normal values for <span class="alt">dexamethasone</span> or <span class="alt">metyrapone</span> tests; may increase serum levels of <span class="alt">glucose,</span> <span class="alt">BSP,</span> and <span class="alt">alkaline phosphatase</span> and may decrease <span class="alt">PBI</span> and <span class="alt">urinary steroid</span> levels.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> decreases mephenytoin effects; <span class="classification">other anticonvulsants</span> may increase or decrease mephenytoin levels; may decrease absorption and increase metabolism of <span class="classification">oral anticoagulants</span>; increases metabolism of <span class="classification">corticosteroids</span>, <span class="classification">oral contraceptives</span>, and <b>nisoldipine,</b> thus decreasing their effectiveness; <b>amiodarone,</b> <b>chloramphenicol,</b> <b>omeprazole,</b> and <b>ticlopidine</b> increase mephenytoin levels; <span class="classification">antituberculosis agents</span> decrease mephenytoin levels. <span class="typehead">Food:</span> Folic acid, calcium, and vitamin D absorption may be decreased mephenytoin absorption may be decreased by enteral nutrition
      supplements. <span class="typehead">Herbal:</span> <b>Ginkgo</b> may decrease anticonvulsant effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 30 min. <span class="typehead">Duration:</span> 2448 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 144 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Keep patients under close supervision at all times; drug is associated with severe adverse effects. Serious blood dyscrasias
            have occurred 2 wk30 mo after initiation of therapy.
         </li>
<li>Lab tests: Baseline liver function, total white cell count, and differential count prior to initiation of therapy. Perform
            blood studies q2 wk and continue until patient is on maintenance dosage for 2 wk; then repeat monthly for 1 y, and thereafter
            every 3 mo (unless neutrophil count drops to 2500/mm<sup>3</sup> or 1600/mm<sup>3</sup>, then performed every 2 wk).
         </li>
<li>Discontinue if neutrophil count falls to 1600/mm<sup>3</sup>.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid potentially hazardous activities until response to drug is known. Be aware that supervision of ambulation may be indicated
            for some patients during early therapy.
         </li>
<li>Report immediately to physician: Onset of drowsiness, ataxia, skin rash, sore throat, fever, mucous membrane bleeding, or
            glandular swelling. All are indications of developing toxic reaction.
         </li>
<li>Discontinue drug gradually to minimize the risk of precipitating seizures or status epilepticus.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>